Cipla Limited (CIPLA) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Appointment of B S R & Co. LLP as statutory auditor for five-year term

💡 Investor Takeaway
The new auditor will oversee financial reporting for the next five years, potentially enhancing audit consistency and investor confidence.

Cipla announced the appointment of B S R & Co. LLP as its new statutory auditor for a five-year term starting from the conclusion of its 90th AGM on 25 June 2026, succeeding Walker Chandiok & Co. LLP which completed its second term. The change aligns with SEBI Listing Regulations requirements and was approved by shareholders at the AGM.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
90th AGM approved FY26 financials and reappointed directors

🔄 What Changed
FY26 revenue reached ₹28,163 crores with ₹5,925 crores EBITDA and ₹3,879 crores PAT, marking double-digit growth; new Vice-Chairman Mr P R Ramesh appointed

🔮 What's Next
Strategic Vision 2031 targets #2 position in IPM by 2031, #1 in respiratory market, and biosimilars expansion

💡 Investor Takeaway
Strong FY26 financials and leadership updates reinforce Cipla's growth trajectory and commitment to affordable healthcare innovation.

Cipla held its 90th Annual General Meeting on 25 June 2026 via video conference, adopting audited standalone and consolidated financial statements for FY26, declaring dividends, reappointing directors, and appointing new auditors. Chairman Dr YK Hamied highlighted 90 years of legacy, pandemic resilience, and ESG milestones, while MD Achin Gupta presented FY26 performance showing ₹28,163 crores revenue, ₹5,925 crores EBITDA, and ₹3,879 crores PAT with double-digit growth across segments. The meeting concluded with all resolutions passed by majority, reaffirming strategic focus on respiratory, oncology, and global expansion through 2031.

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day

Cipla Limited (CIPLA) — Board Meeting(2 announcements)

About Cipla Limited (CIPLA)

Recent Announcements from Cipla Limited